Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 159-168

  Giordano, A ^a  

^a Invasive Cardiology Unit   (Italy)

Author keywords

Drug eluting stent; FK 506 binding protein; FKBP; Sirolimus; Tacrolimus; Vascular smooth muscle cell; VSMC

Indexed keywords

FK 506 BINDING PROTEIN; RAPAMYCIN; TACROLIMUS;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CORONARY ARTERY OBSTRUCTION; DRUG ACTIVITY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL PROLIFERATION; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; PROTEIN BINDING; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 77749270618     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Block PC: Percutaneous transluminal coronary angioplasty. Am J Roentgenol (1980) 135(5):955-959.
2. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, Coady P, Cohen H, Cowley M, Dorros G, Faxon D, et al: Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute Registries. Circulation (2000) 102(24):2945-2951.
3. Prasad A: Mayo Clinic offce visit. Drug-eluting stents. An interview with Abhiram Prasad MD. Mayo Clin Womens Healthsource (2007) 11(5):6.
4. Singh M, Rihal CS, Gersh BJ, Lennon RJ, Prasad A, Sorajja P, Gullerud RE, Holmes DR Jr: Twenty-fve-year trends in in-hospital and long-term outcome after percutaneous coronary intervention: A single-institution experience. Circulation (2007) 115(22):2835-2841.
5. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, et al: Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet (1998) 352(9129):673-768
6. Welt FG, Rogers C: Infammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol (2002) 22(11):1769-1776.
7. Indolf C, Esposito G, Di Lorenzo E, Rapacciuolo A, Feliciello A, Porcellini A, Avvedimento VE, Condorelli M, Chiariello M: Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation (1995) 92(5):1230-1235.
8. Sousa JE, Serruys PW, Costa MA: New frontiers in cardiology: Drug eluting stents: Part I. Circulation (2003) 107(17):2274-2279.
9. Woods TC, Marks AR: Drug-eluting stents. Ann Rev Med (2004) 55:169-178.
10. Costa MA, Simon DI: Molecular basis of restenosis and drug eluting stents. Circulation (2005) 111(17):2257-2273.
11. Abraham RT and WiederrechtC GJ: Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 14:483-510.
12. Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T, Goto T, Okuhara M: Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc (1987) 19(5 Suppl 6):11-16. (Pubitemid 17157072)
13. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell (2000) 103(2):253-262.
14. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest (1996) 98(10):2277-2283.
15. Jayaraman T, Marks AR: Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits Cdc2 kinase activity in a myogenic cell line. J Biol Chem (1993) 268(34):25385-25388.
16. Marx SO, Jayaraman T, Go LO, Marks AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res (1995) 76(3):412-417.
17. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2001) 103(2): 192-195.
18. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW: Coronary restenosis elimination with a sirolimus eluting stent: First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J (2001) 22(22):2125-2130.
19. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 346(23):1773-1780.
20. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 349(14):1315-1323.
21. Morice MC, Bestehorn HP, Carrié D, Macaya C, Aengevaeren W, Wijns W, Dubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, et al: Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention (2006) 2(1):45-52.
22. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grünenfelder J, Zünd G, Tanner FC, et al: Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol (2006) 48(6):286-292.
23. Grube E, Buellesfeld L: Rapamycin analogs for stent-based local drug delivery. Everolimus-and tacrolimus-eluting stents. Herz (2004) 29(2):162-166.
24. Romagnoli E, Leone AM, Burzotta F, Trani C, Angeloni G, Materazzo G, Niccoli G, De Vita M, Perfetti M, Mazzari MA, Mongiardo R, et al: Outcomes of the tacrolimus drug-eluting Janus stent: A prospective two-centre registry in high-risk patients. J Cardiovasc Med (2008) 9(6):589-594.
25. Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, Scardaci F, Ussia G, Galassi AR, Fiscella D, Mehran R, et al: Real world safety and effcacy of the Janus tacrolimus-eluting stent: Long-term clinical outcome and angiographic fndings from the Tacrolimus-Eluting STent (TEST) registry. Catheter Cardiovasc Interv (2009) 73(2):243-248.
26. Sehgal SN, Baker H, Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (1975) 28(10):727-732.
27. Sigal NH, Lin CS, Siekierka JJ: Inhibition of human T-cell activation by FK506, rapamycin, and cyclosporine A. Transplant Proc (1991) 23(2 Suppl 2):1-5.
28. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. (1994) Cell 78(1):35-43.
29. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 341(6244):755-757.
30. Dornan J, Taylor P, Walkinshaw MD: Structures of immunophilins and their ligand complexes. Curr Top Med Chem (2003) 3(12):1392-1409.
31. Somarelli JA, Lee SY, Skolnick J, Herrera RJ: Structure-based classifcation of 45 FK506-binding proteins. Proteins (2008) 72(1):197-208.
32. Standaert RF, Galat A, Verdine GL, Schreiber SL: Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature (1990) 346(6285):671-674.
33. Gothel SF, Marahiel MA: Peptidyl-prolyl cistrans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci (1999) 55(3):423-436.
34. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS: FKBP family proteins: Immunophilins with versatile biological functions. Neurosignals (2008) 16(4):318-325.
35. Meijer AJ, Codogno P: Nutrient sensing: TOR's ragtime. Nat Cell Biol (2008)10(8):881-883.
36. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 369(6483):756-758.
37. Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev (2001) 15(11): 1383-1392.
38. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N: Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev (2001) 15(21):2852-2864.
39. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (1992) 257(5072):973-977.
40. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR: Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol (1996) 16(12):6744-6751.
41. Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol (1997) 15:707-747.
42. Klein M, Klein-Hessling S, Palmetshofer A, Serfing E, Tertilt C, Bopp T, Heib V, Becker M, Taube C, Schild H, Schmitt E, et al:Specifc and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol (2006) 177(10):6667-6674.
43. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR: Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell (1994) 77(4):513-523.
44. 2+ fux. Cell (1995) 83(3):463-472.
45. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK: The immunophilin FKBP12 functions as a common inhibitor of the TGFp family type I receptors. Cell (1996) 86(3):435-444.
46. Chen YG, Liu F, Massague J: Mechanism of TGFp receptor inhibition by FKBP12. EMBO J (1997) 16(13):3866-3876.
47. Long C, Cook LG, Wu GY, Mitchell BM: Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol (2007) 27(7):1580-1586.
48. Cameron AM, Steiner JP, Sabatini DM, Kaplin AI, Walensky LD, Snyder SH: Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium fux. Proc Natl Acad Sci USA (1995) 92(5):1784-1788.
49. Lu KP, Finn G, Lee TH and Nicholson LK: Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol (2007) 3(10):619-629.
50. Nelson CJ, Santos-Rosa H, Kouzarides T: Proline isomerization of histone H3 regulates lysine methylation and gene expression. Cell (2006) 126(5):905-916.
51. Ratajczak T, Ward BK, Minchin RF: Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem (2003) 3(12):1348-1357.
52. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, et al: A physical and functional map of the human TNF./NFi B signal transduction pathway. Nat Cell Biol (2004) 6(2):97-105.
53. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M: Identifcation and characterization of an IκB kinase. Cell (1997) 90(2):373-383.
54. Karin M, Delhase M: The IκB kinase (IKK) and NFκB: Key elements of proinfammatory signalling. Semin Immunol (2000) 12(1):85-98.
55. Ghosh S, Karin M: Missing pieces in the NFκB puzzle. Cell (2002)109(Suppl):S81-S96.
56. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S: Rapamycin inhibits doxorubicin-induced NFκB/Rel nuclear activity and enhances apoptosis in melanoma. Eur J Cancer (2004) 40(18):2829-2836.
57. Massague J, Blain SW, Lo RS: TGFβ signaling in growth control, cancer, and heritable disorders. Cell (2000) 103(2):295-309.
58. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ: Direct transfer of transforming growth factor β1 gene into arteries stimulates fbrocellular hyperplasia. Proc Natl Acad Sci USA (1993) 90(22):10759-10763.
59. Schulick AH, Taylor AJ, Zuo W, Qiu C-B, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA: Overexpression of transforming growth factor p1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA (1998) 95(12):6983-6988.
60. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-p1 suppress intimal hyperplasia in a rat model. J Clin Invest (1994) 93(3):1172-1178.
61. Giordano A, Romano S, Mallardo M, D'Angelillo A, Calì G, Corcione N, Ferraro P, Romano MF: Overexpression of transforming growth factor p1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia Cardiovasc Res (2008) 79(3):519-526.
62. Massagué J, Wotton D: Transcriptional control by the TGFp/Smad signaling system. EMBO J (2000) 19(8):1745-1754.
63. Tanaka H, Sukhova G, Schwartz D, Libby P: Proliferating arterial smooth muscle cells after balloon injury express TNF but not interleukin-1 or basic fbroblast growth factor. Arterioscler Thromb Vasc Biol (1996) 16(1):12-18.
64. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol (1999) 17:331-367.
65. Guo D, Donner DB: Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem (1996) 271(2):615-618.
66. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNFa-induced apoptosis by NFi B. Science (1996) 274(5288):787-789.
67. Mehrhof FB, Schmidt-Ullrich R, Dietz R, Scheidereit C: Regulation of vascular smooth muscle cell proliferation: Role of NFKB revisited. Circ Res (2005) 96(9):958-964.
68. Giordano A, Avellino R, Ferraro P, Romano S, Corcione N, Romano MF: Rapamycin antagonizes NFi B nuclear translocation activated by TNF in primary vascular smooth muscle cells and enhances apoptosis. Am J Physiol Heart Circ Physiol (2006) 290(6):H2459-H2465.
69. L and Bf-1/A1. Am J Physiol Cell Physiol (2002) 283(2):C422-C428.
70. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, Bourgeois S: FKBP51, a novel T-cell specifc immunophilin capable of calcineurin inhibition. Mol Cell Biol (1995) 15(8): 4395-4402.
71. Yingling JM, Blanchard KL, Sawyer JS: Development of TGFp signalling inhibitors for cancer therapy. Nat Rev Drug Discov (2004) 3(12):1011-1022.
72. Romano MF: Targeting TGF|-mediated processes in cancer. Curr Opin Drug Discov Devel (2009) 12(2):253-263.
73. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, Vogel D, Grinfeld R, Delacasa A, Garrido M, Oliveri R, et al: Argentine randomized study: Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30 day and one-year follow-up results. J Am Coll Cardiol (2001) 37(1):51-58.
74. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, et al: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med (2001) 344(15):1117-1124. (Pubitemid 32285232)
75. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, et al: Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation (2004) 109(9):1114-1120.
76. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med (2006) 355(19):1949-1952.
77. Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents. J Am Coll Cardiol (2008)51:1844-1853
78. Ako J, Bonneau HN, Honda Y, Fitzgerald PJ: Design criteria for the ideal drug-eluting stent. Am J Cardiol (2007) 100(8B): 3M-9M.
79. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S: Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 115(18):2426-2434.
80. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA: Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2007) 70(4):515-523.
81. Kastrati A: Drug for a while, polymer for life: Is it a good solution? Catheter Cardiovasc Interv (2008) 71(3):340-341.
82. John M, Finn AV, Wessely R, Kastrati A, Joner M, Uchihashi M, Crimins J, Kolodgie F, Listhrop R, Gold HK, Schomig A, et al: Comparison of overlapping non-polymer versus polymer-based DES: Finding a better balance between neointimal suppression and arterial healing. Circulation (2006) 114(II-643-II-644):Abs 3054.
83. Anderson JM: Biological responses to materials. Annu Rev Mater Res (2001) 31:81-110.
84. Grube E, Sievert H, Hauptmann KE, Mueller R, Gerckens U, Buellesfeld L, Ako J, Shimohama T, Costa M, Fitzgerald P: Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. EuroIntervention (2008) 4(1):71-76.
85. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE: Randomized, doubleblind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 114(8):798-806.
86. Uurto I, Mikkonen J, Parkkinen J, Keski-Nisula L, Nevalainen T, Kellomäki M, Törmälä P, Salenius JP: Drug-eluting biodegradable poly-d/l-lactic acid vascular stents: An experimental pilot study. J Endovasc Ther (2005) 12(3):371-379.
87. Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A: Six-month results of a randomized study to evaluate safety and effcacy of a biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention (2005) 1(1): 53-57.
88. 14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials (1992) 13(15):1093-1102.
89. Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, et al: Angiographic results of the frst human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol (2006) 98(4):443-446.
90. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, Nedeljkovic M, Orlic D, Milosavljevic B, Topic D, Karanovic N, et al: Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol (2008) 51(22):2123-2129.
91. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, et al: Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet (2008) 372(9644):1163-1173.
92. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A: A polymer-free dual drug-eluting stent in patients with coronary artery disease: A randomized trial vs polymer-based drug-eluting stents. Eur Heart J (2009) 30(8):923-931.
93. Tamburino C, Capodanno D: Evolution of stents: Past, present and future. Expert Rev Cardiovasc Ther (2009) 7(5):443-446.
94. CID OPTIMA tacrolimus eluting carbostent. CID Srl, Saluggia, Italy (2010). cidvascular.com/optima.php
95. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, et al: Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA (2008) 299(16):1903-1913.
96. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, et al: Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation (2009) 119(5):680-686.
97. Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, et al: First clinical comparison of NOBORI-biolimus A9 eluting stents with Cypher-sirolimus eluting stents: NOBORI core nine months angiographic and one year clinical outcomes. EuroIntervention (2008) 3(5):574-579.
98. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, et al: Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet (2008) 372(9644):1163-1173.
99. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ; ENDEAVOR III Investigators: Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (randomized controlled trial of the medtronic endeavor drug [ABT-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv (2009) 2(12):1199-1207.
100. Waksman R, Pakala R, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Tittelbach M, Diener T, Harder C, Virmani R, et al: Effcacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. Cardiovasc Revasc Med (2007) 8(4):259-274.